SRR26320068
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- WNT_BETA_CATENIN_SIGNALING+0.320
- MYOGENESIS+0.300
- HEDGEHOG_SIGNALING+0.280
- TGF_BETA_SIGNALING+0.200
- ALLOGRAFT_REJECTION+0.160
- APICAL_JUNCTION+0.160
- COAGULATION+0.140
- COMPLEMENT+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.530
- MTORC1_SIGNALING-0.460
- MYC_TARGETS_V1-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.390
- DNA_REPAIR-0.360
- GLYCOLYSIS-0.360
- PEROXISOME-0.330
- OXIDATIVE_PHOSPHORYLATION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.939 |
| 2 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.936 |
| 3 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.900 |
| 4 | SRR15069598 | — | — | 0.896 |
| 5 | SRR11296806 | — | — | 0.894 |
| 6 | MBCProject_1493_T1_RNA | — | A | 0.891 |
| 7 | DRR168573 | — | — | 0.884 |
| 8 | SRR975557 | — | — | 0.880 |
| 9 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.876 |
| 10 | SRR9879291 | — | cohortMD2 | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |